From the Guidelines
Buprenorphine, a partial opioid agonist, is best treated by continuing the medication perioperatively, with consideration of tapering to 12 mg daily over 2 to 3 days preoperatively for higher doses (>12 mg daily) often prescribed for the treatment of opioid use disorders, as recommended by the Perioperative Pain and Addiction Interdisciplinary Network 1. The treatment of buprenorphine involves a comprehensive approach, including medication-assisted treatment with buprenorphine or methadone maintenance therapy in combination with behavioral therapies, as well as consideration of the patient's individual needs and circumstances.
- Key considerations include:
- The patient's opioid use disorder diagnosis and treatment plan
- The potential risks and benefits of continuing or tapering buprenorphine
- The importance of maintaining patient comfort and valued activities during the treatment process
- The need for close monitoring and follow-up evaluation to ensure complete resolution and prevent recurrence According to a recent systematic review, there is a lack of high-quality evidence on the perioperative management of buprenorphine, but the available data suggest that continuing buprenorphine perioperatively is a safe and effective approach 1.
- Additional studies have shown that buprenorphine has safety advantages over full mu agonists, including a lower risk of respiratory depression and overdose 1.
- The American College of Obstetricians and Gynecologists and the American Society of Addiction Medicine recommend that pregnant women with opioid use disorder receive medication-assisted therapy with buprenorphine or methadone, as it has been associated with improved maternal outcomes 1.
- The Substance Abuse and Mental Health Services Administration (SAMHSA) provides resources and guidance for clinicians on the treatment of opioid use disorder, including the use of buprenorphine and methadone, as well as the importance of arranging for patients to receive care from a substance use disorder treatment specialist 1.
From the Research
Treatment for Bula (Buprenorphine)
There are no research papers provided that directly discuss the treatment for Bula (Buprenorphine, a partial opioid agonist). The studies available are related to:
- Parkinson's disease 2
- Evidence-based research 3, 4
- Physical activity guidelines for Americans 5
- Depression 6
These studies do not provide information on the treatment for Bula (Buprenorphine). Key points from the available studies include:
- Parkinson's disease treatment goals vary from person to person, emphasizing the need for personalized management 2
- Evidence-based research ensures worthwhile and valuable research by using prior research in a systematic and transparent way 3, 4
- Physical activity guidelines for Americans provide information and guidance on the types and amounts of physical activity to improve health outcomes for multiple population groups 5
- Depression is a common illness that severely limits psychosocial functioning and diminishes quality of life, with challenges in detection, diagnosis, and management 6